Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
King RM, Vidrine DJ, Danysh HE, Fletcher FE, McCurdy S, Arduino RC, Gritz ER. Factors associated with nonadherence to antiretroviral therapy in HIV-positive smokers. AIDS Patient Care STDS. 2012 Aug;26(8):479-85. doi: 10.1089/apc.2012.0070
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Finkelstein EA, Kosa KM. Use of incentives to motivate healthy behaviors among employees. Gender issues. 2003 Jun;21(3):50-9. doi: 10.1007/s12147-003-0005-0
Poole WK, Pollack M, Rapoport I, Williams V, Koch MA, Rao AV, Bartel DA. Use of Multivariate Methods in Quantifying the Variability in the Perception of Neonatal Intensive Care Unit Characteristics in Nine Hospitals in the Washington, DC Area: the NIH-DC Initiative to Reduce Infant Mortality in Minority Populations in the District of Columbia. Interstat. 2002 Jan 1.